nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—blood vessel—colon cancer	0.0166	0.122	CbGeAlD
Everolimus—MTOR—embryo—colon cancer	0.00989	0.0727	CbGeAlD
Everolimus—MTOR—epithelium—colon cancer	0.00807	0.0593	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—colon cancer	0.00778	0.0572	CbGeAlD
Everolimus—MTOR—renal system—colon cancer	0.00749	0.055	CbGeAlD
Everolimus—FKBP1A—epithelium—colon cancer	0.00726	0.0534	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—colon cancer	0.00699	0.0514	CbGeAlD
Everolimus—FKBP1A—renal system—colon cancer	0.00673	0.0495	CbGeAlD
Everolimus—MTOR—lymphoid tissue—colon cancer	0.00622	0.0457	CbGeAlD
Everolimus—MTOR—digestive system—colon cancer	0.00614	0.0451	CbGeAlD
Everolimus—MTOR—bone marrow—colon cancer	0.00566	0.0416	CbGeAlD
Everolimus—FKBP1A—lymphoid tissue—colon cancer	0.00559	0.0411	CbGeAlD
Everolimus—FKBP1A—digestive system—colon cancer	0.00552	0.0406	CbGeAlD
Everolimus—MTOR—vagina—colon cancer	0.00542	0.0399	CbGeAlD
Everolimus—FKBP1A—bone marrow—colon cancer	0.00509	0.0374	CbGeAlD
Everolimus—FKBP1A—vagina—colon cancer	0.00488	0.0359	CbGeAlD
Everolimus—MTOR—liver—colon cancer	0.00457	0.0336	CbGeAlD
Everolimus—FKBP1A—liver—colon cancer	0.00411	0.0302	CbGeAlD
Everolimus—MTOR—lymph node—colon cancer	0.00351	0.0258	CbGeAlD
Everolimus—FKBP1A—lymph node—colon cancer	0.00315	0.0232	CbGeAlD
Everolimus—Temsirolimus—ABCB1—colon cancer	0.00253	0.362	CrCbGaD
Everolimus—Sirolimus—ABCB1—colon cancer	0.00223	0.319	CrCbGaD
Everolimus—Tacrolimus—ABCB1—colon cancer	0.00223	0.319	CrCbGaD
Everolimus—CYP3A4—renal system—colon cancer	0.0022	0.0162	CbGeAlD
Everolimus—CYP3A4—digestive system—colon cancer	0.0018	0.0133	CbGeAlD
Everolimus—CYP3A4—liver—colon cancer	0.00134	0.00988	CbGeAlD
Everolimus—Stomatitis—Capecitabine—colon cancer	0.0005	0.00095	CcSEcCtD
Everolimus—Infection—Vincristine—colon cancer	0.000499	0.000948	CcSEcCtD
Everolimus—Urinary tract infection—Capecitabine—colon cancer	0.000499	0.000948	CcSEcCtD
Everolimus—Conjunctivitis—Capecitabine—colon cancer	0.000499	0.000948	CcSEcCtD
Everolimus—Convulsion—Fluorouracil—colon cancer	0.000497	0.000945	CcSEcCtD
Everolimus—Nervous system disorder—Vincristine—colon cancer	0.000492	0.000935	CcSEcCtD
Everolimus—Thrombocytopenia—Vincristine—colon cancer	0.000492	0.000934	CcSEcCtD
Everolimus—Haematuria—Capecitabine—colon cancer	0.000489	0.00093	CcSEcCtD
Everolimus—Oedema—Irinotecan—colon cancer	0.000489	0.000929	CcSEcCtD
Everolimus—Myalgia—Fluorouracil—colon cancer	0.000489	0.000928	CcSEcCtD
Everolimus—Chest pain—Fluorouracil—colon cancer	0.000489	0.000928	CcSEcCtD
Everolimus—Infection—Irinotecan—colon cancer	0.000486	0.000923	CcSEcCtD
Everolimus—Hyperhidrosis—Vincristine—colon cancer	0.000485	0.000922	CcSEcCtD
Everolimus—Hepatobiliary disease—Capecitabine—colon cancer	0.000485	0.000922	CcSEcCtD
Everolimus—Epistaxis—Capecitabine—colon cancer	0.000484	0.00092	CcSEcCtD
Everolimus—Discomfort—Fluorouracil—colon cancer	0.000483	0.000917	CcSEcCtD
Everolimus—Shock—Irinotecan—colon cancer	0.000481	0.000914	CcSEcCtD
Everolimus—Nervous system disorder—Irinotecan—colon cancer	0.00048	0.000911	CcSEcCtD
Everolimus—Thrombocytopenia—Irinotecan—colon cancer	0.000479	0.00091	CcSEcCtD
Everolimus—Anorexia—Vincristine—colon cancer	0.000479	0.000909	CcSEcCtD
Everolimus—Irritability—Methotrexate—colon cancer	0.000473	0.000899	CcSEcCtD
Everolimus—Hyperhidrosis—Irinotecan—colon cancer	0.000473	0.000898	CcSEcCtD
Everolimus—Hypotension—Vincristine—colon cancer	0.000469	0.000891	CcSEcCtD
Everolimus—Oedema—Fluorouracil—colon cancer	0.000468	0.00089	CcSEcCtD
Everolimus—Anorexia—Irinotecan—colon cancer	0.000466	0.000886	CcSEcCtD
Everolimus—Infection—Fluorouracil—colon cancer	0.000465	0.000884	CcSEcCtD
Everolimus—Haemoglobin—Capecitabine—colon cancer	0.000463	0.00088	CcSEcCtD
Everolimus—Rhinitis—Capecitabine—colon cancer	0.000462	0.000877	CcSEcCtD
Everolimus—Haemorrhage—Capecitabine—colon cancer	0.000461	0.000875	CcSEcCtD
Everolimus—Hepatitis—Capecitabine—colon cancer	0.000461	0.000875	CcSEcCtD
Everolimus—Nervous system disorder—Fluorouracil—colon cancer	0.000459	0.000873	CcSEcCtD
Everolimus—Thrombocytopenia—Fluorouracil—colon cancer	0.000459	0.000871	CcSEcCtD
Everolimus—Hypoaesthesia—Capecitabine—colon cancer	0.000458	0.000871	CcSEcCtD
Everolimus—Liver function test abnormal—Methotrexate—colon cancer	0.000458	0.000869	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Vincristine—colon cancer	0.000458	0.000869	CcSEcCtD
Everolimus—Pharyngitis—Capecitabine—colon cancer	0.000457	0.000869	CcSEcCtD
Everolimus—Tachycardia—Fluorouracil—colon cancer	0.000457	0.000868	CcSEcCtD
Everolimus—Hypotension—Irinotecan—colon cancer	0.000457	0.000868	CcSEcCtD
Everolimus—Urinary tract disorder—Capecitabine—colon cancer	0.000455	0.000864	CcSEcCtD
Everolimus—Insomnia—Vincristine—colon cancer	0.000454	0.000863	CcSEcCtD
Everolimus—Oedema peripheral—Capecitabine—colon cancer	0.000454	0.000862	CcSEcCtD
Everolimus—Connective tissue disorder—Capecitabine—colon cancer	0.000453	0.00086	CcSEcCtD
Everolimus—Urethral disorder—Capecitabine—colon cancer	0.000452	0.000858	CcSEcCtD
Everolimus—Paraesthesia—Vincristine—colon cancer	0.000451	0.000857	CcSEcCtD
Everolimus—Breast disorder—Methotrexate—colon cancer	0.000448	0.000851	CcSEcCtD
Everolimus—Anorexia—Fluorouracil—colon cancer	0.000446	0.000848	CcSEcCtD
Everolimus—Insomnia—Irinotecan—colon cancer	0.000442	0.00084	CcSEcCtD
Everolimus—Paraesthesia—Irinotecan—colon cancer	0.000439	0.000834	CcSEcCtD
Everolimus—Hypotension—Fluorouracil—colon cancer	0.000438	0.000831	CcSEcCtD
Everolimus—Decreased appetite—Vincristine—colon cancer	0.000437	0.000829	CcSEcCtD
Everolimus—Dyspnoea—Irinotecan—colon cancer	0.000436	0.000828	CcSEcCtD
Everolimus—Somnolence—Irinotecan—colon cancer	0.000435	0.000826	CcSEcCtD
Everolimus—Gastrointestinal disorder—Vincristine—colon cancer	0.000434	0.000824	CcSEcCtD
Everolimus—Fatigue—Vincristine—colon cancer	0.000433	0.000822	CcSEcCtD
Everolimus—Eye disorder—Capecitabine—colon cancer	0.000431	0.000818	CcSEcCtD
Everolimus—Dyspepsia—Irinotecan—colon cancer	0.000431	0.000818	CcSEcCtD
Everolimus—Constipation—Vincristine—colon cancer	0.000429	0.000816	CcSEcCtD
Everolimus—Pain—Vincristine—colon cancer	0.000429	0.000816	CcSEcCtD
Everolimus—Flushing—Capecitabine—colon cancer	0.000428	0.000812	CcSEcCtD
Everolimus—Cardiac disorder—Capecitabine—colon cancer	0.000428	0.000812	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.000427	0.000811	CcSEcCtD
Everolimus—Decreased appetite—Irinotecan—colon cancer	0.000425	0.000808	CcSEcCtD
Everolimus—Insomnia—Fluorouracil—colon cancer	0.000424	0.000805	CcSEcCtD
Everolimus—Gastrointestinal disorder—Irinotecan—colon cancer	0.000422	0.000802	CcSEcCtD
Everolimus—Fatigue—Irinotecan—colon cancer	0.000422	0.000801	CcSEcCtD
Everolimus—Paraesthesia—Fluorouracil—colon cancer	0.000421	0.000799	CcSEcCtD
Everolimus—Pancreatitis—Methotrexate—colon cancer	0.00042	0.000798	CcSEcCtD
Everolimus—Pain—Irinotecan—colon cancer	0.000418	0.000794	CcSEcCtD
Everolimus—Constipation—Irinotecan—colon cancer	0.000418	0.000794	CcSEcCtD
Everolimus—Angiopathy—Capecitabine—colon cancer	0.000418	0.000794	CcSEcCtD
Everolimus—Dyspnoea—Fluorouracil—colon cancer	0.000418	0.000793	CcSEcCtD
Everolimus—Somnolence—Fluorouracil—colon cancer	0.000416	0.000791	CcSEcCtD
Everolimus—Immune system disorder—Capecitabine—colon cancer	0.000416	0.00079	CcSEcCtD
Everolimus—Mediastinal disorder—Capecitabine—colon cancer	0.000415	0.000789	CcSEcCtD
Everolimus—Chills—Capecitabine—colon cancer	0.000413	0.000785	CcSEcCtD
Everolimus—Dyspepsia—Fluorouracil—colon cancer	0.000412	0.000783	CcSEcCtD
Everolimus—Gastrointestinal pain—Vincristine—colon cancer	0.000411	0.00078	CcSEcCtD
Everolimus—Decreased appetite—Fluorouracil—colon cancer	0.000407	0.000773	CcSEcCtD
Everolimus—Alopecia—Capecitabine—colon cancer	0.000407	0.000773	CcSEcCtD
Everolimus—Pancytopenia—Methotrexate—colon cancer	0.000407	0.000773	CcSEcCtD
Everolimus—Gastrointestinal disorder—Fluorouracil—colon cancer	0.000404	0.000768	CcSEcCtD
Everolimus—Mental disorder—Capecitabine—colon cancer	0.000404	0.000767	CcSEcCtD
Everolimus—Feeling abnormal—Irinotecan—colon cancer	0.000403	0.000766	CcSEcCtD
Everolimus—Malnutrition—Capecitabine—colon cancer	0.000401	0.000762	CcSEcCtD
Everolimus—Erythema—Capecitabine—colon cancer	0.000401	0.000762	CcSEcCtD
Everolimus—Dysuria—Methotrexate—colon cancer	0.000401	0.000761	CcSEcCtD
Everolimus—Neutropenia—Methotrexate—colon cancer	0.000401	0.000761	CcSEcCtD
Everolimus—Pain—Fluorouracil—colon cancer	0.000401	0.000761	CcSEcCtD
Everolimus—Gastrointestinal pain—Irinotecan—colon cancer	0.0004	0.00076	CcSEcCtD
Everolimus—Upper respiratory tract infection—Methotrexate—colon cancer	0.000398	0.000756	CcSEcCtD
Everolimus—Body temperature increased—Vincristine—colon cancer	0.000397	0.000754	CcSEcCtD
Everolimus—Abdominal pain—Vincristine—colon cancer	0.000397	0.000754	CcSEcCtD
Everolimus—Flatulence—Capecitabine—colon cancer	0.000395	0.000751	CcSEcCtD
Everolimus—Erectile dysfunction—Methotrexate—colon cancer	0.000395	0.00075	CcSEcCtD
Everolimus—Dysgeusia—Capecitabine—colon cancer	0.000393	0.000746	CcSEcCtD
Everolimus—Back pain—Capecitabine—colon cancer	0.000388	0.000737	CcSEcCtD
Everolimus—Body temperature increased—Irinotecan—colon cancer	0.000387	0.000734	CcSEcCtD
Everolimus—Abdominal pain—Irinotecan—colon cancer	0.000387	0.000734	CcSEcCtD
Everolimus—Feeling abnormal—Fluorouracil—colon cancer	0.000386	0.000733	CcSEcCtD
Everolimus—Muscle spasms—Capecitabine—colon cancer	0.000386	0.000732	CcSEcCtD
Everolimus—Pneumonia—Methotrexate—colon cancer	0.000384	0.00073	CcSEcCtD
Everolimus—Infestation NOS—Methotrexate—colon cancer	0.000382	0.000726	CcSEcCtD
Everolimus—Infestation—Methotrexate—colon cancer	0.000382	0.000726	CcSEcCtD
Everolimus—Vision blurred—Capecitabine—colon cancer	0.000378	0.000718	CcSEcCtD
Everolimus—Tremor—Capecitabine—colon cancer	0.000376	0.000714	CcSEcCtD
Everolimus—Renal failure—Methotrexate—colon cancer	0.000376	0.000713	CcSEcCtD
Everolimus—Stomatitis—Methotrexate—colon cancer	0.000372	0.000707	CcSEcCtD
Everolimus—Ill-defined disorder—Capecitabine—colon cancer	0.000372	0.000707	CcSEcCtD
Everolimus—Conjunctivitis—Methotrexate—colon cancer	0.000371	0.000705	CcSEcCtD
Everolimus—Anaemia—Capecitabine—colon cancer	0.000371	0.000704	CcSEcCtD
Everolimus—Body temperature increased—Fluorouracil—colon cancer	0.00037	0.000703	CcSEcCtD
Everolimus—Hypersensitivity—Vincristine—colon cancer	0.00037	0.000703	CcSEcCtD
Everolimus—Haematuria—Methotrexate—colon cancer	0.000364	0.000692	CcSEcCtD
Everolimus—Malaise—Capecitabine—colon cancer	0.000362	0.000687	CcSEcCtD
Everolimus—Hepatobiliary disease—Methotrexate—colon cancer	0.000361	0.000686	CcSEcCtD
Everolimus—Epistaxis—Methotrexate—colon cancer	0.00036	0.000685	CcSEcCtD
Everolimus—Hypersensitivity—Irinotecan—colon cancer	0.00036	0.000684	CcSEcCtD
Everolimus—Asthenia—Vincristine—colon cancer	0.00036	0.000684	CcSEcCtD
Everolimus—Syncope—Capecitabine—colon cancer	0.00036	0.000683	CcSEcCtD
Everolimus—Leukopenia—Capecitabine—colon cancer	0.000359	0.000682	CcSEcCtD
Everolimus—Palpitations—Capecitabine—colon cancer	0.000354	0.000673	CcSEcCtD
Everolimus—Loss of consciousness—Capecitabine—colon cancer	0.000353	0.00067	CcSEcCtD
Everolimus—Asthenia—Irinotecan—colon cancer	0.000351	0.000667	CcSEcCtD
Everolimus—Cough—Capecitabine—colon cancer	0.00035	0.000665	CcSEcCtD
Everolimus—Hypertension—Capecitabine—colon cancer	0.000346	0.000658	CcSEcCtD
Everolimus—Hypersensitivity—Fluorouracil—colon cancer	0.000345	0.000656	CcSEcCtD
Everolimus—Haemoglobin—Methotrexate—colon cancer	0.000345	0.000655	CcSEcCtD
Everolimus—Diarrhoea—Vincristine—colon cancer	0.000344	0.000653	CcSEcCtD
Everolimus—Haemorrhage—Methotrexate—colon cancer	0.000343	0.000651	CcSEcCtD
Everolimus—Hepatitis—Methotrexate—colon cancer	0.000343	0.000651	CcSEcCtD
Everolimus—Chest pain—Capecitabine—colon cancer	0.000341	0.000649	CcSEcCtD
Everolimus—Arthralgia—Capecitabine—colon cancer	0.000341	0.000649	CcSEcCtD
Everolimus—Myalgia—Capecitabine—colon cancer	0.000341	0.000649	CcSEcCtD
Everolimus—Pharyngitis—Methotrexate—colon cancer	0.00034	0.000647	CcSEcCtD
Everolimus—Anxiety—Capecitabine—colon cancer	0.00034	0.000646	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.000339	0.000644	CcSEcCtD
Everolimus—Urinary tract disorder—Methotrexate—colon cancer	0.000339	0.000643	CcSEcCtD
Everolimus—Discomfort—Capecitabine—colon cancer	0.000337	0.000641	CcSEcCtD
Everolimus—Urethral disorder—Methotrexate—colon cancer	0.000336	0.000639	CcSEcCtD
Everolimus—Diarrhoea—Irinotecan—colon cancer	0.000335	0.000636	CcSEcCtD
Everolimus—Dry mouth—Capecitabine—colon cancer	0.000334	0.000634	CcSEcCtD
Everolimus—Dizziness—Vincristine—colon cancer	0.000332	0.000631	CcSEcCtD
Everolimus—Pruritus—Fluorouracil—colon cancer	0.000331	0.000629	CcSEcCtD
Everolimus—Oedema—Capecitabine—colon cancer	0.000327	0.000622	CcSEcCtD
Everolimus—Infection—Capecitabine—colon cancer	0.000325	0.000618	CcSEcCtD
Everolimus—Dizziness—Irinotecan—colon cancer	0.000323	0.000614	CcSEcCtD
Everolimus—Shock—Capecitabine—colon cancer	0.000322	0.000612	CcSEcCtD
Everolimus—Nervous system disorder—Capecitabine—colon cancer	0.000321	0.00061	CcSEcCtD
Everolimus—Eye disorder—Methotrexate—colon cancer	0.000321	0.000609	CcSEcCtD
Everolimus—Diarrhoea—Fluorouracil—colon cancer	0.00032	0.000609	CcSEcCtD
Everolimus—Thrombocytopenia—Capecitabine—colon cancer	0.00032	0.000609	CcSEcCtD
Everolimus—Tachycardia—Capecitabine—colon cancer	0.000319	0.000607	CcSEcCtD
Everolimus—Vomiting—Vincristine—colon cancer	0.000319	0.000607	CcSEcCtD
Everolimus—Cardiac disorder—Methotrexate—colon cancer	0.000318	0.000605	CcSEcCtD
Everolimus—Skin disorder—Capecitabine—colon cancer	0.000318	0.000604	CcSEcCtD
Everolimus—Rash—Vincristine—colon cancer	0.000317	0.000601	CcSEcCtD
Everolimus—Hyperhidrosis—Capecitabine—colon cancer	0.000316	0.000601	CcSEcCtD
Everolimus—Dermatitis—Vincristine—colon cancer	0.000316	0.000601	CcSEcCtD
Everolimus—Headache—Vincristine—colon cancer	0.000315	0.000598	CcSEcCtD
Everolimus—Anorexia—Capecitabine—colon cancer	0.000312	0.000593	CcSEcCtD
Everolimus—Angiopathy—Methotrexate—colon cancer	0.000311	0.000591	CcSEcCtD
Everolimus—Vomiting—Irinotecan—colon cancer	0.000311	0.000591	CcSEcCtD
Everolimus—Immune system disorder—Methotrexate—colon cancer	0.00031	0.000588	CcSEcCtD
Everolimus—Dizziness—Fluorouracil—colon cancer	0.00031	0.000588	CcSEcCtD
Everolimus—Mediastinal disorder—Methotrexate—colon cancer	0.000309	0.000587	CcSEcCtD
Everolimus—Rash—Irinotecan—colon cancer	0.000308	0.000586	CcSEcCtD
Everolimus—Dermatitis—Irinotecan—colon cancer	0.000308	0.000585	CcSEcCtD
Everolimus—Chills—Methotrexate—colon cancer	0.000308	0.000585	CcSEcCtD
Everolimus—Headache—Irinotecan—colon cancer	0.000306	0.000582	CcSEcCtD
Everolimus—Hypotension—Capecitabine—colon cancer	0.000306	0.000581	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MYC—colon cancer	0.000304	0.00092	CbGpPWpGaD
Everolimus—Alopecia—Methotrexate—colon cancer	0.000303	0.000576	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—colon cancer	0.000301	0.000911	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—colon cancer	0.000301	0.000909	CbGpPWpGaD
Everolimus—Mental disorder—Methotrexate—colon cancer	0.0003	0.000571	CcSEcCtD
Everolimus—MTOR—B Cell Activation—CDKN1A—colon cancer	0.000299	0.000904	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—SRC—colon cancer	0.000299	0.000904	CbGpPWpGaD
Everolimus—Malnutrition—Methotrexate—colon cancer	0.000299	0.000567	CcSEcCtD
Everolimus—Erythema—Methotrexate—colon cancer	0.000299	0.000567	CcSEcCtD
Everolimus—Nausea—Vincristine—colon cancer	0.000298	0.000567	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Capecitabine—colon cancer	0.000298	0.000566	CcSEcCtD
Everolimus—MTOR—PI-3K cascade—AKT1—colon cancer	0.000298	0.000901	CbGpPWpGaD
Everolimus—Vomiting—Fluorouracil—colon cancer	0.000298	0.000566	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—colon cancer	0.000297	0.0009	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—HRAS—colon cancer	0.000297	0.000898	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KRAS—colon cancer	0.000297	0.000898	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—SRC—colon cancer	0.000296	0.000896	CbGpPWpGaD
Everolimus—Insomnia—Capecitabine—colon cancer	0.000296	0.000562	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—EGFR—colon cancer	0.000296	0.000895	CbGpPWpGaD
Everolimus—Rash—Fluorouracil—colon cancer	0.000295	0.000561	CcSEcCtD
Everolimus—Dermatitis—Fluorouracil—colon cancer	0.000295	0.00056	CcSEcCtD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—colon cancer	0.000295	0.000892	CbGpPWpGaD
Everolimus—Paraesthesia—Capecitabine—colon cancer	0.000294	0.000558	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—SRC—colon cancer	0.000293	0.000888	CbGpPWpGaD
Everolimus—Headache—Fluorouracil—colon cancer	0.000293	0.000557	CcSEcCtD
Everolimus—Dysgeusia—Methotrexate—colon cancer	0.000292	0.000555	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—SRC—colon cancer	0.000292	0.000884	CbGpPWpGaD
Everolimus—Dyspnoea—Capecitabine—colon cancer	0.000292	0.000554	CcSEcCtD
Everolimus—MTOR—PI3K/AKT activation—AKT1—colon cancer	0.000291	0.00088	CbGpPWpGaD
Everolimus—Nausea—Irinotecan—colon cancer	0.000291	0.000552	CcSEcCtD
Everolimus—Back pain—Methotrexate—colon cancer	0.000289	0.000549	CcSEcCtD
Everolimus—MTOR—GAB1 signalosome—AKT1—colon cancer	0.000289	0.000873	CbGpPWpGaD
Everolimus—Dyspepsia—Capecitabine—colon cancer	0.000288	0.000547	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—NRAS—colon cancer	0.000287	0.00087	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—NRAS—colon cancer	0.000287	0.00087	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—colon cancer	0.000287	0.00087	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—CDKN1A—colon cancer	0.000286	0.000865	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—NRAS—colon cancer	0.000285	0.000862	CbGpPWpGaD
Everolimus—Decreased appetite—Capecitabine—colon cancer	0.000285	0.00054	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—KRAS—colon cancer	0.000284	0.000859	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Capecitabine—colon cancer	0.000283	0.000537	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—EGFR—colon cancer	0.000282	0.000855	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—NRAS—colon cancer	0.000282	0.000854	CbGpPWpGaD
Everolimus—Fatigue—Capecitabine—colon cancer	0.000282	0.000536	CcSEcCtD
Everolimus—MTOR—ErbB1 downstream signaling—AKT1—colon cancer	0.000282	0.000853	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—colon cancer	0.000282	0.000853	CbGpPWpGaD
Everolimus—Vision blurred—Methotrexate—colon cancer	0.000281	0.000534	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—colon cancer	0.000281	0.00085	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—colon cancer	0.000281	0.00085	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—NRAS—colon cancer	0.000281	0.00085	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—colon cancer	0.000281	0.00085	CbGpPWpGaD
Everolimus—Pain—Capecitabine—colon cancer	0.00028	0.000532	CcSEcCtD
Everolimus—Constipation—Capecitabine—colon cancer	0.00028	0.000532	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—EGFR—colon cancer	0.00028	0.000846	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KRAS—colon cancer	0.000279	0.000845	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—EGFR—colon cancer	0.000278	0.000842	CbGpPWpGaD
Everolimus—Nausea—Fluorouracil—colon cancer	0.000278	0.000528	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—colon cancer	0.000278	0.00084	CbGpPWpGaD
Everolimus—Ill-defined disorder—Methotrexate—colon cancer	0.000277	0.000526	CcSEcCtD
Everolimus—Anaemia—Methotrexate—colon cancer	0.000276	0.000524	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—colon cancer	0.000274	0.00083	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—PIK3CA—colon cancer	0.000273	0.000825	CbGpPWpGaD
Everolimus—Feeling abnormal—Capecitabine—colon cancer	0.00027	0.000512	CcSEcCtD
Everolimus—Malaise—Methotrexate—colon cancer	0.000269	0.000511	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—AXIN2—colon cancer	0.000268	0.000812	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Capecitabine—colon cancer	0.000268	0.000508	CcSEcCtD
Everolimus—MTOR—Immune System—BCL10—colon cancer	0.000268	0.00081	CbGpPWpGaD
Everolimus—Leukopenia—Methotrexate—colon cancer	0.000267	0.000508	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—KRAS—colon cancer	0.000267	0.000807	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NRAS—colon cancer	0.000266	0.000805	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—colon cancer	0.000266	0.000803	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KRAS—colon cancer	0.000266	0.000803	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—SRC—colon cancer	0.000265	0.000801	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KRAS—colon cancer	0.000264	0.000799	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KRAS—colon cancer	0.000263	0.000796	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—AKT1—colon cancer	0.000262	0.000793	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—colon cancer	0.000262	0.000792	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—colon cancer	0.000262	0.000792	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—EGFR—colon cancer	0.000262	0.000792	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—PIK3CA—colon cancer	0.000261	0.000789	CbGpPWpGaD
Everolimus—Cough—Methotrexate—colon cancer	0.000261	0.000495	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—EGFR—colon cancer	0.00026	0.000785	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—colon cancer	0.000259	0.000784	CbGpPWpGaD
Everolimus—Body temperature increased—Capecitabine—colon cancer	0.000259	0.000492	CcSEcCtD
Everolimus—Abdominal pain—Capecitabine—colon cancer	0.000259	0.000492	CcSEcCtD
Everolimus—Convulsion—Methotrexate—colon cancer	0.000259	0.000491	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—colon cancer	0.000257	0.000778	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—PIK3CA—colon cancer	0.000257	0.000777	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—EGFR—colon cancer	0.000256	0.000775	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—colon cancer	0.000255	0.00077	CbGpPWpGaD
Everolimus—Arthralgia—Methotrexate—colon cancer	0.000254	0.000483	CcSEcCtD
Everolimus—Chest pain—Methotrexate—colon cancer	0.000254	0.000483	CcSEcCtD
Everolimus—Myalgia—Methotrexate—colon cancer	0.000254	0.000483	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.000252	0.00048	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—colon cancer	0.000252	0.000763	CbGpPWpGaD
Everolimus—Discomfort—Methotrexate—colon cancer	0.000251	0.000477	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—colon cancer	0.00025	0.000755	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—HRAS—colon cancer	0.000248	0.00075	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—colon cancer	0.000247	0.000748	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KRAS—colon cancer	0.000247	0.000748	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KRAS—colon cancer	0.000247	0.000748	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—PIK3CA—colon cancer	0.000246	0.000745	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—PIK3CA—colon cancer	0.000245	0.000742	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—KRAS—colon cancer	0.000245	0.000742	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—PIK3CA—colon cancer	0.000244	0.000738	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—KRAS—colon cancer	0.000243	0.000735	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—PIK3CA—colon cancer	0.000243	0.000734	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—EGFR—colon cancer	0.000242	0.000733	CbGpPWpGaD
Everolimus—Infection—Methotrexate—colon cancer	0.000242	0.00046	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—KRAS—colon cancer	0.000242	0.000732	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD8A—colon cancer	0.000242	0.000731	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—PIK3CA—colon cancer	0.000242	0.000731	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—colon cancer	0.000241	0.00073	CbGpPWpGaD
Everolimus—Hypersensitivity—Capecitabine—colon cancer	0.000241	0.000458	CcSEcCtD
Everolimus—Nervous system disorder—Methotrexate—colon cancer	0.000239	0.000454	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—colon cancer	0.000239	0.000453	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—PIK3CA—colon cancer	0.000238	0.00072	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—HRAS—colon cancer	0.000238	0.000719	CbGpPWpGaD
Everolimus—Skin disorder—Methotrexate—colon cancer	0.000237	0.00045	CcSEcCtD
Everolimus—Hyperhidrosis—Methotrexate—colon cancer	0.000236	0.000447	CcSEcCtD
Everolimus—Asthenia—Capecitabine—colon cancer	0.000235	0.000446	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CDKN1A—colon cancer	0.000234	0.000709	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CASP3—colon cancer	0.000234	0.000707	CbGpPWpGaD
Everolimus—Anorexia—Methotrexate—colon cancer	0.000232	0.000441	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—colon cancer	0.000232	0.000702	CbGpPWpGaD
Everolimus—Pruritus—Capecitabine—colon cancer	0.000232	0.00044	CcSEcCtD
Everolimus—MTOR—B Cell Activation—KRAS—colon cancer	0.000229	0.000693	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—HRAS—colon cancer	0.000228	0.00069	CbGpPWpGaD
Everolimus—Hypotension—Methotrexate—colon cancer	0.000228	0.000433	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—PIK3CA—colon cancer	0.000227	0.000688	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—PIK3CA—colon cancer	0.000227	0.000688	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—PIK3CA—colon cancer	0.000227	0.000688	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—HRAS—colon cancer	0.000227	0.000686	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—colon cancer	0.000226	0.000683	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—HRAS—colon cancer	0.000226	0.000683	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—PIK3CA—colon cancer	0.000225	0.000681	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—HRAS—colon cancer	0.000225	0.000679	CbGpPWpGaD
Everolimus—Diarrhoea—Capecitabine—colon cancer	0.000224	0.000425	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—HRAS—colon cancer	0.000223	0.000676	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—PIK3CA—colon cancer	0.000223	0.000675	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—EP300—colon cancer	0.000223	0.000675	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—AKT1—colon cancer	0.000223	0.000674	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—PIK3CA—colon cancer	0.000222	0.000672	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Methotrexate—colon cancer	0.000222	0.000422	CcSEcCtD
Everolimus—Insomnia—Methotrexate—colon cancer	0.00022	0.000419	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—colon cancer	0.00022	0.000666	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CDKN1A—colon cancer	0.00022	0.000665	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—colon cancer	0.000219	0.000663	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—AKT1—colon cancer	0.000219	0.000663	CbGpPWpGaD
Everolimus—Paraesthesia—Methotrexate—colon cancer	0.000219	0.000416	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—colon cancer	0.000217	0.000413	CcSEcCtD
Everolimus—Somnolence—Methotrexate—colon cancer	0.000217	0.000411	CcSEcCtD
Everolimus—Dizziness—Capecitabine—colon cancer	0.000216	0.000411	CcSEcCtD
Everolimus—MTOR—Innate Immune System—BCL2L1—colon cancer	0.000215	0.000652	CbGpPWpGaD
Everolimus—Dyspepsia—Methotrexate—colon cancer	0.000214	0.000407	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—AKT1—colon cancer	0.000213	0.000645	CbGpPWpGaD
Everolimus—Decreased appetite—Methotrexate—colon cancer	0.000212	0.000402	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—VEGFA—colon cancer	0.000211	0.000639	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—colon cancer	0.000211	0.000638	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Methotrexate—colon cancer	0.00021	0.0004	CcSEcCtD
Everolimus—MTOR—B Cell Activation—PIK3CA—colon cancer	0.00021	0.000636	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—colon cancer	0.00021	0.000636	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—colon cancer	0.00021	0.000636	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—colon cancer	0.00021	0.000636	CbGpPWpGaD
Everolimus—Fatigue—Methotrexate—colon cancer	0.00021	0.000399	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—AKT1—colon cancer	0.00021	0.000634	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—colon cancer	0.000208	0.00063	CbGpPWpGaD
Everolimus—Pain—Methotrexate—colon cancer	0.000208	0.000396	CcSEcCtD
Everolimus—Vomiting—Capecitabine—colon cancer	0.000208	0.000395	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—colon cancer	0.000207	0.000625	CbGpPWpGaD
Everolimus—Rash—Capecitabine—colon cancer	0.000206	0.000392	CcSEcCtD
Everolimus—Dermatitis—Capecitabine—colon cancer	0.000206	0.000392	CcSEcCtD
Everolimus—MTOR—Innate Immune System—FGFR3—colon cancer	0.000206	0.000623	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—HRAS—colon cancer	0.000206	0.000622	CbGpPWpGaD
Everolimus—Headache—Capecitabine—colon cancer	0.000205	0.00039	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—SRC—colon cancer	0.000204	0.000616	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—colon cancer	0.000201	0.000609	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—AKT1—colon cancer	0.000201	0.000609	CbGpPWpGaD
Everolimus—Feeling abnormal—Methotrexate—colon cancer	0.000201	0.000381	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—AKT1—colon cancer	0.0002	0.000606	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—AKT1—colon cancer	0.000199	0.000603	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—colon cancer	0.000199	0.000603	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Methotrexate—colon cancer	0.000199	0.000378	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—AKT1—colon cancer	0.000198	0.0006	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGFR3—colon cancer	0.000198	0.000598	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—AKT1—colon cancer	0.000197	0.000597	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGFR3—colon cancer	0.000197	0.000596	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—NRAS—colon cancer	0.000196	0.000592	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA7—colon cancer	0.000196	0.000592	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—HRAS—colon cancer	0.000195	0.000589	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—colon cancer	0.000195	0.000588	CbGpPWpGaD
Everolimus—Nausea—Capecitabine—colon cancer	0.000194	0.000369	CcSEcCtD
Everolimus—Body temperature increased—Methotrexate—colon cancer	0.000193	0.000366	CcSEcCtD
Everolimus—Abdominal pain—Methotrexate—colon cancer	0.000193	0.000366	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—colon cancer	0.000186	0.000563	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—colon cancer	0.000186	0.000562	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—colon cancer	0.000186	0.000562	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—colon cancer	0.000186	0.000562	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—AKT1—colon cancer	0.000184	0.000557	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—colon cancer	0.000182	0.000552	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT1—colon cancer	0.000182	0.000549	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APC—colon cancer	0.000181	0.000547	CbGpPWpGaD
Everolimus—Hypersensitivity—Methotrexate—colon cancer	0.00018	0.000341	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—EGFR—colon cancer	0.000178	0.00054	CbGpPWpGaD
Everolimus—Asthenia—Methotrexate—colon cancer	0.000175	0.000332	CcSEcCtD
Everolimus—Pruritus—Methotrexate—colon cancer	0.000172	0.000327	CcSEcCtD
Everolimus—MTOR—B Cell Activation—AKT1—colon cancer	0.000172	0.00052	CbGpPWpGaD
Everolimus—FKBP1A—Disease—BRAF—colon cancer	0.00017	0.000514	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KRAS—colon cancer	0.000169	0.00051	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDH1—colon cancer	0.000167	0.000505	CbGpPWpGaD
Everolimus—Diarrhoea—Methotrexate—colon cancer	0.000167	0.000317	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—colon cancer	0.000164	0.000497	CbGpPWpGaD
Everolimus—Dizziness—Methotrexate—colon cancer	0.000161	0.000306	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—colon cancer	0.00016	0.000483	CbGpPWpGaD
Everolimus—Vomiting—Methotrexate—colon cancer	0.000155	0.000294	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—PIK3CA—colon cancer	0.000155	0.000468	CbGpPWpGaD
Everolimus—Rash—Methotrexate—colon cancer	0.000154	0.000292	CcSEcCtD
Everolimus—Dermatitis—Methotrexate—colon cancer	0.000153	0.000292	CcSEcCtD
Everolimus—Headache—Methotrexate—colon cancer	0.000153	0.00029	CcSEcCtD
Everolimus—MTOR—Immune System—CD8A—colon cancer	0.000147	0.000444	CbGpPWpGaD
Everolimus—Nausea—Methotrexate—colon cancer	0.000145	0.000275	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—HRAS—colon cancer	0.000143	0.000433	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGFR3—colon cancer	0.000138	0.000417	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—colon cancer	0.000137	0.000415	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CTNNB1—colon cancer	0.000128	0.000389	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APC—colon cancer	0.000127	0.000383	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—colon cancer	0.000126	0.000383	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CDKN1A—colon cancer	0.000125	0.00038	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2L1—colon cancer	0.000125	0.00038	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CTNNB1—colon cancer	0.000123	0.000372	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDKN1A—colon cancer	0.00012	0.000364	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CDKN1A—colon cancer	0.00012	0.000363	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGFR3—colon cancer	0.00012	0.000363	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EP300—colon cancer	0.000119	0.000361	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BRAF—colon cancer	0.000119	0.00036	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ODC1—colon cancer	0.000119	0.000359	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CHST5—colon cancer	0.000119	0.000359	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—SRC—colon cancer	0.000116	0.000351	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EP300—colon cancer	0.000114	0.000345	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NRAS—colon cancer	0.000112	0.000338	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—SRC—colon cancer	0.000111	0.000337	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SRC—colon cancer	0.000111	0.000336	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR3—colon cancer	0.000111	0.000335	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRAS—colon cancer	0.000107	0.000324	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—colon cancer	0.000107	0.000323	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—colon cancer	0.000102	0.000308	CbGpPWpGaD
Everolimus—MTOR—Disease—APC—colon cancer	0.000102	0.000308	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDH1—colon cancer	0.000101	0.000307	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—colon cancer	9.95e-05	0.000301	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—colon cancer	9.92e-05	0.0003	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—colon cancer	9.77e-05	0.000296	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—colon cancer	9.73e-05	0.000294	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—colon cancer	9.61e-05	0.000291	CbGpPWpGaD
Everolimus—MTOR—Disease—BRAF—colon cancer	9.56e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—colon cancer	9.23e-05	0.000279	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—colon cancer	9.19e-05	0.000278	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—colon cancer	8.92e-05	0.00027	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—colon cancer	8.83e-05	0.000267	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—colon cancer	8.68e-05	0.000263	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CTNNB1—colon cancer	8.6e-05	0.00026	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—colon cancer	8.48e-05	0.000257	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—colon cancer	8.44e-05	0.000255	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CDKN1A—colon cancer	8.4e-05	0.000254	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—colon cancer	8.17e-05	0.000247	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EP300—colon cancer	7.99e-05	0.000242	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—colon cancer	7.85e-05	0.000237	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—colon cancer	7.81e-05	0.000236	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SRC—colon cancer	7.77e-05	0.000235	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR3—colon cancer	7.75e-05	0.000235	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—colon cancer	7.72e-05	0.000234	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—colon cancer	7.57e-05	0.000229	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTNNB1—colon cancer	7.48e-05	0.000226	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—colon cancer	7.48e-05	0.000226	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDKN1A—colon cancer	7.31e-05	0.000221	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—colon cancer	7.21e-05	0.000218	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APC—colon cancer	7.12e-05	0.000215	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—colon cancer	6.96e-05	0.000211	CbGpPWpGaD
Everolimus—MTOR—Immune System—EP300—colon cancer	6.95e-05	0.00021	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—colon cancer	6.95e-05	0.00021	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—colon cancer	6.93e-05	0.00021	CbGpPWpGaD
Everolimus—MTOR—Disease—CTNNB1—colon cancer	6.91e-05	0.000209	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—colon cancer	6.9e-05	0.000209	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—colon cancer	6.81e-05	0.000206	CbGpPWpGaD
Everolimus—MTOR—Immune System—SRC—colon cancer	6.76e-05	0.000205	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN1A—colon cancer	6.75e-05	0.000204	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BRAF—colon cancer	6.69e-05	0.000202	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—colon cancer	6.5e-05	0.000197	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—colon cancer	6.44e-05	0.000195	CbGpPWpGaD
Everolimus—MTOR—Disease—EP300—colon cancer	6.42e-05	0.000194	CbGpPWpGaD
Everolimus—MTOR—Disease—SRC—colon cancer	6.24e-05	0.000189	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—colon cancer	6.01e-05	0.000182	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—colon cancer	5.93e-05	0.000179	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—colon cancer	5.91e-05	0.000179	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—colon cancer	5.72e-05	0.000173	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—colon cancer	5.6e-05	0.000169	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—colon cancer	5.59e-05	0.000169	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—colon cancer	5.58e-05	0.000169	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—colon cancer	5.47e-05	0.000166	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—colon cancer	5.47e-05	0.000165	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—colon cancer	5.17e-05	0.000156	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—colon cancer	5.14e-05	0.000156	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—colon cancer	5.02e-05	0.000152	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—colon cancer	4.88e-05	0.000148	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNB1—colon cancer	4.84e-05	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—colon cancer	4.83e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—colon cancer	4.76e-05	0.000144	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—colon cancer	4.75e-05	0.000144	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN1A—colon cancer	4.72e-05	0.000143	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EP300—colon cancer	4.5e-05	0.000136	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—colon cancer	4.39e-05	0.000133	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SRC—colon cancer	4.37e-05	0.000132	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—colon cancer	4.26e-05	0.000129	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—colon cancer	4.21e-05	0.000127	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—colon cancer	4.2e-05	0.000127	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—colon cancer	3.92e-05	0.000119	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—colon cancer	3.91e-05	0.000118	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—colon cancer	3.88e-05	0.000117	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—colon cancer	3.83e-05	0.000116	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—colon cancer	3.62e-05	0.00011	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—colon cancer	3.33e-05	0.000101	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—colon cancer	3.22e-05	9.73e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCB1—colon cancer	3.13e-05	9.48e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMS—colon cancer	3.08e-05	9.31e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—colon cancer	3.08e-05	9.31e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—colon cancer	2.72e-05	8.22e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—colon cancer	2.18e-05	6.59e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—colon cancer	1.71e-05	5.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—EP300—colon cancer	1.43e-05	4.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—colon cancer	1.05e-05	3.19e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—colon cancer	8.62e-06	2.61e-05	CbGpPWpGaD
